CheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
University of Hong Kong · National Cancer Center · +18 more institutions
Indexed incrossref
Abstract
No abstract available for this paper.
Citation impact
646
total citations
- FWCI
- 73.43
- Percentile
- 100%
- References
- 0
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Sorafenib
- Nivolumab
- Hepatocellular carcinoma
- Internal medicine
- Oncology
- First line
- Gastroenterology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.